1. PCSK9 inhibitor therapy should be considered for ASCVD risk reduction in patients with stable atherosclerotic cardiovascular disease, particularly in those with additional ASCVD risk factors, on maximally-tolerated statin therapy ± ezetimibe, with on-treatment LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL. Strength A, Quality: High 2. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients with progressive atherosclerotic cardiovascular disease on maximally tolerated-statin therapy ± ezetimibe, and on-treatment LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL. Strength B, Quality: Moderate Phenotypic FH/LDL-C ≥ 190 mg/dL 3a. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients age 40-79 years with phenotypic FH, pre-treatment LDL-C ≥ 190 mg/dL, no uncontrolled ASCVD risk factors or other key additional high risk markers*, and on-treatment LDL-C ≥ 100 mg/dL or non-HDL-C ≥ 130 mg/dL on maximal-tolerated statin therapy ± ezetimibe. Strength B, Quality: Moderate 3b. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients age 40-79 years with phenotypic FH, pre-treatment LDL-C ≥ 190 mg/dL and the presence of either uncontrolled ASCVD risk factors, key additional high risk markers*, or genetic confirmation of familial hypercholesterolemia, and on-treatment LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL on maximal-tolerated statin ± ezetimibe. Strength: B, Quality: Moderate 3c. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients age 18-39 years with phenotypic FH, pre-treatment LDL-C ≥ 190 mg/dL and the presence of either uncontrolled ASCVD risk factors, key additional high risk markers*, or genetic confirmation of familial hypercholesterolemia, and on-treatment LDL-C ≥ 100 mg/dL or non-HDL-C ≥ 130 mg/dL on maximal-tolerated statin ± ezetimibe. Strength: E, Quality: Low 3d. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients with homozygous familial hypercholesterolemia, either of unknown genotype, or those known to be LDL receptor defective, on maximaltolerated statin therapy ± ezetimibe with LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL. Strength B, Quality: Moderate Very High Risk/Statin Intolerance 4. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in selected very high-risk patients who meet the definition of statin intolerance (as previously defined by the NLA Statin Expert Panel) and who require substantial additional atherogenic cholesterol lowering, despite the use of other lipid lowering therapies. Strength C, Quality: Low * Including history of uncontrolled high blood pressure, diabetes, current cigarette smoking or family history of premature ASCVD; or additional high risk markers (coronary calcium ≥ 300 Agatston units [or ≥ 75 th percentile for the patient's age, gender and ethnicity]; Lp(a) ≥ 50 mg/dL using an isoform insensitive assay, hs-CRP ≥ 2 mg/L or CKD including albumin/creatinine ratio ≥ 30 mg/g)
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Recommendations of the NLA Expert Panel on Treatment with PCSK9 Inhibitors ASCVD 1. PCSK9 inhibitor therapy should be considered for ASCVD risk reduction in patients with stable atherosclerotic cardiovascular disease, particularly in those with additional ASCVD risk factors, on maximally-tolerated statin therapy ± ezetimibe, with on-treatment LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL. Strength A, Quality: High 2. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients with progressive atherosclerotic cardiovascular disease on maximally tolerated-statin therapy ± ezetimibe, and on-treatment LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL. Strength B, Quality: Moderate Phenotypic FH/LDL-C ≥ 190 mg/dL 3a. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients age 40-79 years with phenotypic FH, pre-treatment LDL-C ≥ 190 mg/dL, no uncontrolled ASCVD risk factors or other key additional high risk markers*, and on-treatment LDL-C ≥ 100 mg/dL or non-HDL-C ≥ 130 mg/dL on maximal-tolerated statin therapy ± ezetimibe. Strength B, Quality: Moderate 3b. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients age 40-79 years with phenotypic FH, pre-treatment LDL-C ≥ 190 mg/dL and the presence of either uncontrolled ASCVD risk factors, key additional high risk markers*, or genetic confirmation of familial hypercholesterolemia, and on-treatment LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL on maximal-tolerated statin ± ezetimibe. Strength: B, Quality: Moderate 3c. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients age 18-39 years with phenotypic FH, pre-treatment LDL-C ≥ 190 mg/dL and the presence of either uncontrolled ASCVD risk factors, key additional high risk markers*, or genetic confirmation of familial hypercholesterolemia, and on-treatment LDL-C ≥ 100 mg/dL or non-HDL-C ≥ 130 mg/dL on maximal-tolerated statin ± ezetimibe. Strength: E, Quality: Low 3d. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients with homozygous familial hypercholesterolemia, either of unknown genotype, or those known to be LDL receptor defective, on maximaltolerated statin therapy ± ezetimibe with LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL. Strength B, Quality: Moderate Very High Risk/Statin Intolerance 4. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in selected very high-risk patients who meet the definition of statin intolerance (as previously defined by the NLA Statin Expert Panel) and who require substantial additional atherogenic cholesterol lowering, despite the use of other lipid lowering therapies. Strength C, Quality: Low * Including history of uncontrolled high blood pressure, diabetes, current cigarette smoking or family history of premature ASCVD; or additional high risk markers (coronary calcium ≥ 300 Agatston units [or ≥ 75 th percentile for the patient's age, gender and ethnicity]; Lp(a) ≥ 50 mg/dL using an isoform insensitive assay, hs-CRP ≥ 2 mg/L or CKD including albumin/creatinine ratio ≥ 30 mg/g)
